Pharmacokinetic studies on diponium bromide.

Area of Science:

• Pharmacokinetics and Drug Metabolism
• Biochemistry

Background:

• Understanding the disposition of intravenously administered pharmaceuticals is crucial for optimizing therapeutic efficacy and safety.
• Diponium bromide (DB) is a quaternary ammonium compound with potential pharmacological applications requiring detailed kinetic and metabolic profiling.

Purpose of the Study:

• To elucidate the body elimination kinetics of diponium bromide following intravenous administration.
• To identify the metabolic pathways and excreted forms of diponium bromide in humans.

Main Methods:

• Intravenous administration of diponium bromide to human volunteers.
• Pharmacokinetic analysis including distribution half-life, elimination rate, distribution volume, and clearance.
• Metabolite identification in urine and feces using thin-layer chromatography (TLC).
• In vitro assessment of erythrocyte and plasma protein binding.

Main Results:

• Rapid alpha-distribution phase with a t 1/2 of 4 to 11 minutes.
• Elimination rate varied between 2.3 and 7.7 hours; distribution volume was 29.64 ± 15.03 L.
• Total body clearance averaged 72.99 ± 28.52 ml/min, with renal clearance at 45.03 ± 12.51 ml/min.
• TLC identified unchanged DB and one metabolite in urine, and three metabolites in feces.
• Diponium bromide demonstrated no binding to erythrocytes but did bind to plasma proteins.

Conclusions:

• Diponium bromide undergoes rapid distribution and has a moderate elimination half-life in the body.
• The primary routes of elimination involve both renal clearance and metabolic transformation, with varying metabolite profiles in urine and feces.
• Plasma protein binding influences the overall disposition of diponium bromide, while erythrocyte interaction is negligible.